COVID-19 With COPD: Fewer Hospitalizations, But Greater Mortality
Chronic obstructive pulmonary disease may be associated with higher rates of mortality in patients with coronavirus disease 2019.
Chronic obstructive pulmonary disease may be associated with higher rates of mortality in patients with coronavirus disease 2019.
The incidence and prevalence of a first-ever spontaneous pneumothorax in patients with chronic obstructive pulmonary disease (COPD) and emphysema are increased significantly in men and in Black patients.
The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
Antiplatelet therapy may delay progression of COPD, decrease the risk for acute exacerbations, improve quality of life, and even reduce all-cause mortality.
The use of regular, low-dose, oral sustained-release morphine for 4 weeks in patients with COPD and moderate to very severe breathlessness has been shown to improve disease-specific health status.
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
Patients with COPD who received a metered dose inhaler containing budesonide, glycopyrrolate, and formoterol fumarate showed lung function improvements through 52 weeks.
Nebulized ensifentrine, when added to tiotropium, produced clinically meaningful and significant improvements in lung function and quality of life in patients with COPD.
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
Median prevalence of any underlying medical condition 47.2% for residents in all 50 states, DC.